At a glance
ClinicalIndex Comparison RecordN/ACompleted· 544 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Month Noninterventional, Postmarketing, Multicenter Study to Evaluate the Effectiveness of Briviact® (Brivaracetam) as Adjunctive Therapy in Patients With Epilepsy With Partial-onset Seizures in Daily Clinical Practice
In Brief
An observational study for Epilepsy With POS With or Without Secondary Generalization. Completed, enrolled 544 participants across 44 sites in 9 countries.
Detailed Summary
Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesDenmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
CollaboratorsPharm Research Associates Ltd. UK
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedFeb 2016
Primary CompletionJul 2020
TodayJul 2026
First PostedFeb 22, 2016
Enrollment StartFeb 1, 2016
Primary CompletionJul 15, 2020
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 10.4 years ago